Revance Therapeutics is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection.
The data showcased novel findings from the SAKURA Phase 3 program evaluating DaxibotulinumtoxinA for Injection for the treatment of moderate or severe frown lines, as well as a four-week interim analysis from the Phase 2a open-label study for the treatment of moderate to severe lateral canthal lines (LCL).
The first presentation, "DaxibotulinumtoxinA for Injection Demonstrates Consistent Efficacy, Duration, and Safety in Females Independent of Age: Subgroup Analysis from a Large, Phase 3 Program," presented by Glynis Ablon, MD, FAAD, dermatologist at Ablon Skin Institute and Research Center, Manhattan Beach, CA, and associate clinical professor at University of California, Los Angeles, reported on the efficacy, duration and safety of DaxibotulinumtoxinA for Injection in females across multiple age cohorts following the treatment of glabellar lines in the SAKURA program. This subgroup analysis demonstrated that the efficacy and duration of DaxibotulinumtoxinA for Injection for the treatment of glabellar lines is similarly high in adult females independent of age.
The second presentation, "DaxibotulinumtoxinA for Injection-treated subjects show progressive improvement in static glabellar lines with repeated treatment," presented by Richard Glogau, MD, dermatologist at Glogau Dermatology, San Francisco, and clinical professor of dermatology University of California, San Francisco, highlighted details from the SAKURA program in which DaxibotulinumtoxinA for Injection-treated subjects showed substantial and progressive improvement in the severity of glabellar lines at rest following repeated treatment.
The third presentation, "DaxibotulinumtoxinA for Injection for Lateral Canthal Lines: A 4-week Interim Analysis," presented by Terrence Keaney, M.D., FAAD, dermatologist at SkinDC Cosmetic Center, Arlington, VA, and assistant clinical faculty of dermatology at George Washington University and Howard University, covered 4-week interim data from the Phase 2a open-label study in crow's feet. Data demonstrated that following treatment of LCLs with DaxibotulinumtoxinA for Injection, 88% of subjects achieved a score of none or mild at Week 4 in at least one treatment group. DaxibotulinumtoxinA for Injection appeared to be well tolerated at all dose levels.
“These data underscore the potential of DaxibotulinumtoxinA for Injection to set a new standard in facial aesthetics treatments and advance our mission of transforming the patient experience,” said Roman Rubio, senior vice president of clinical development at Revance. “The data from the LCL study were used to optimize our Phase 2 open-label upper facial lines study, which we expect to report results from in the fourth quarter of 2020. Additionally, these findings support our overarching scientific platform as we continue to establish a new category of long-lasting neuromodulator products for our prestige aesthetics portfolio.”